Clinical trials: Dermatologic Diseases
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Breast Cancer, Axillary Lymphadenitis
Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study
Patients with breast cancer and metastatic axillary lymphadenopathy routinely undergo neo-adjuvant chemotherapy. For these patients, biopsy clip markers are inserted into the biopsy proven metastatic lymph node pre-treatment, as…
- Trial name
- NCT04136496
- Testing
- Black-Eye Ink
- Where
- Canada
- Sponsor
- The Ottawa Hospital
Breast Cancer Female
Personalized Vaccine for Cancer Immunotherapy
Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene [called triple-negative breast cancer (TNTC)] and other tumors such as melanoma…
- Trial name
- NCT04879888
- Testing
- Peptide pulsed Dendritic cell
- Where
- Colombia
- Volunteers
- 9 people
- Sponsor
- Universidad Nacional de Colombia
Cancer Survivor, Central Obesity
Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer
This randomized phase II trial studies how well exercise intervention works in targeting adiposity and inflammation with movement to improve prognosis in stage I-III breast cancer survivors.
- Conditions
- Cancer Survivor, Central Obesity, Estrogen Receptor Positive, Postmenopausal
- Trial name
- NCT03091842
- Testing
- Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Southern California
Bladder Cancer, Melanoma
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
- Trial name
- NCT02553642
- Testing
- Nivolumab, Nivolumab plus Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Skin Neoplasms
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma.
- Trial name
- NCT00027586
- Testing
- Imatinib mesylate (STI571)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and…
- Trial name
- NCT00943670
- Testing
- pertuzumab, Trastuzumab emtansine [Kadcyla]
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Melanoma Metastatic, Melanoma Recurrent
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)
The OTIMAS study is a phase II trial designed to evaluate if the duration of one year of pembrolizumab immunotherapy for advanced metastatic melanoma has equivalent efficacy as the two-year duration of historical controls.
- Conditions
- Melanoma Metastatic, Melanoma Recurrent, Cutaneous Melanoma, Stage IV Melanoma
- Trial name
- OTIMAS (NCT07376317)
- Testing
- Pembrolizumab
- Where
- Brazil
- Volunteers
- 29 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Oral Lichen Planus
Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy
Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa and is considered a precancerous condition.
- Trial name
- NCT05973097
- Testing
- total glucosides of paeony treatment, photodynamic therapy treatment, glucosides of paeony and photodynamic therapy combined treatment
- Where
- China
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Breast Neoplasm
Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer
Most women with early breast cancer are treated with breast conserving therapy (BCT), consisting of breast conserving surgery (surgery to remove the cancer itself) followed by radiation to the breast.
- Trial name
- ARTEMIS (NCT02065960)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Juravinski Cancer Center
Malignant Melanoma Stage IV
Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
The purpose of this study is to evaluate the activity of Vemurafenib in combination with Fotemustine in Patients with unresectable Stage IV melanoma harboring V600 BRAF mutation who recurred while in treatment with Vemurafenib.
- Trial name
- BeyPro1 (NCT01983124)
- Testing
- Fotemustine + Vemurafenib
- Where
- 2 sites in Italy
- Volunteers
- 31 people
- Sponsor
- Paola Queirolo
Dermatitis, Atopic
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis
Comparison of Protopic Ointment to Elidel Cream to assess the safety and efficacy in pediatric patients with Atopic Dermatitis
- Trial name
- NCT00666159
- Testing
- tacrolimus ointment, pimecrolimus cream
- Where
- 12 sites in United States
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Inc
Cutaneous Leishmaniasis
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
This study is a pivotal Phase 3, randomized, double-blind, 3-site, two-group trial assessing the efficacy and safety of WR 279,396 Topical Cream and Paromomycin Alone Topical Cream in subjects with CL in Panama.
- Trial name
- NCT01790659
- Testing
- WR 279,396, Paromomycin
- Where
- Panama
- Volunteers
- 399 people
- Sponsor
- U.S. Army Medical Research and Development Command
Breast Cancer Survivor
The INFLUENCE of PHYSICAL ACTIVITY on the HEALTH and WELL-BEING of BREAST CANCER SURVIVORS
Introduction: Cancer remains a leading cause of death globally, with breast cancer being the most common type among women worldwide. The risk of breast cancer is influenced by genetic and lifestyle factors.
- Trial name
- PAF-SBM (NCT06672380)
- Testing
- Remote Physical Exercise Program for Breast Cancer Survivors, Initial Consultation and Exercise Guidance via Ebook for Women Surviving Breast Cance, Initial Incentive for Eating Habits in Women Surviving Breast Cancer
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- Federal University of Bahia
Hair Loss, Nails, Ingrown
Evaluation of the Efficacy of a New Supplement for Hair and Nails - in Vitro, Clinical, Subjective and Instrumental Study
A unicentric, exploratory, prospective clinical an in vitro study to evaluate efficacy and safety of a Supplement in improving the quality and general aspects of hair and nails in female participants through clinical,in vitro…
- Trial name
- NCT05945979
- Testing
- A power supplement with biotin
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Farmoquimica S.A.
Breast Cancer
Acute Exercise Cardioprotection From Doxorubicin
In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to treat breast cancer prevents or attenuates a number of markers of cardiac injury.
- Trial name
- NCT02006979
- Testing
- exercise
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
Onchocerciasis
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O.
- Trial name
- NCT03876262
- Testing
- Moxidectin, Ivermectin
- Where
- Democratic Republic of the Congo
- Volunteers
- 323 people
- Sponsor
- Medicines Development for Global Health
Exanthema, Dengue Fever
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an…
- Conditions
- Exanthema, Dengue Fever, Chikungunya, Measles
- Trial name
- CRIUS (NCT07112846)
- Volunteers
- 830 people
- Sponsor
- Hospital Israelita Albert Einstein
Breast Cancer, Prostate Cancer
Adherence to Oral Therapies in Advanced Breast and Prostate Cancers
AdOTAC is a pilot study, open, prospective, single-center, one-arm. The 200 patients will be included. Patient is included at Day 0.
- Trial name
- AdOTAC (NCT06435546)
- Testing
- Blood samples, Adherence to anti-cancer therapies questionnaires
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut de Cancérologie de Lorraine
Malignant Melanoma
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with different adjuvants.
- Trial name
- NCT00651703
- Testing
- CYT004-MelQbG10 + Montanide, CYT004-MelQbG10 + Montanide + Imiquimod, CYT004-MelQbG10 + Imiquimod
- Where
- 2 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Cytos Biotechnology AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.